ES2180758T3 - Vacunas de pertussis acelulares y metodos de preparacion de las mismas. - Google Patents

Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Info

Publication number
ES2180758T3
ES2180758T3 ES96911887T ES96911887T ES2180758T3 ES 2180758 T3 ES2180758 T3 ES 2180758T3 ES 96911887 T ES96911887 T ES 96911887T ES 96911887 T ES96911887 T ES 96911887T ES 2180758 T3 ES2180758 T3 ES 2180758T3
Authority
ES
Spain
Prior art keywords
pertussis
preparation
fimbrial
vaccines
accelular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96911887T
Other languages
English (en)
Inventor
Raafat E F Fahim
John R Vose
John Thipphawong
Luis Barreto
Gail E D Jackson
Larry U L Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2180758T3 publication Critical patent/ES2180758T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PREPARA UNA PREPARACION DE AGLUTINOGENO FIMBRIAL A PARTIR DE UNA CEPA DE BORDETELLA, EN PARTICULAR UNA CEPA DE B. PERTUSSIS, MEDIANTE UN PROCEDIMIENTO DE MULTIPLES ETAPAS DE IMPLICA LA EXTRACCION DE LOS AGLUTINOGENOS FIMBRIALES DE UNA PASTA CELULAR Y LA CONCENTRACION Y PURIFICACION DEL MATERIAL EXTRAIDO. LA PREPARACION DE AGLUTINOGENOS FIMBRIALES PUEDE UTILIZARSE PARA PREPARAR VACUNAS DE PERTUSSIS ACELULARES CON OTROS AGENTES DE PERTUSSIS, INCLUYENDO LA TOXINA O EL TOXOIDE DE PERTUSSIS, LA PROTEINA DE 69 KDA Y HEMAGLUTININA FILAMENTOSA Y OTROS ANTIGENOS DE BORDETELLA. TALES VACUNAS CONFIEREN PROTECCION A AL MENOS UN 70 % DE LA POBLACION HUMANA DE RIESGO.
ES96911887T 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas. Expired - Lifetime ES2180758T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12

Publications (1)

Publication Number Publication Date
ES2180758T3 true ES2180758T3 (es) 2003-02-16

Family

ID=27029924

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96911887T Expired - Lifetime ES2180758T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
ES96911886T Expired - Lifetime ES2182971T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96911886T Expired - Lifetime ES2182971T3 (es) 1995-05-04 1996-05-02 Vacunas de pertussis acelulares y metodos de preparacion de las mismas.

Country Status (17)

Country Link
US (1) US6399076B2 (es)
EP (7) EP1393744B1 (es)
CN (2) CN1198099A (es)
AT (3) ATE221081T1 (es)
AU (2) AU715417B2 (es)
BR (2) BR9608115A (es)
CA (3) CA2433502A1 (es)
DE (3) DE69638326D1 (es)
DK (3) DK0824358T3 (es)
ES (2) ES2180758T3 (es)
FR (1) FR16C0015I2 (es)
LU (1) LU93036I2 (es)
MX (1) MX9708481A (es)
NL (1) NL300804I2 (es)
NZ (2) NZ306391A (es)
PT (3) PT1393744E (es)
WO (2) WO1996034623A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
CA2188424A1 (en) * 1994-04-28 1995-11-09 Akihiro Suehara Method of separating protective components of bordetella pertussis
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
AU2004292547B9 (en) * 2003-11-20 2012-04-26 Sanofi Pasteur, Inc. Methods for purifying pertussis toxin and peptides useful therefor
PT1828378E (pt) * 2004-12-17 2014-10-10 Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Sport Deacilação de lps em bactérias de gram negativo
EP1942932B1 (en) 2005-08-08 2013-05-08 Oregon Health and Science University Inactivating pathogens with hydrogen peroxide for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
US8574589B2 (en) 2009-05-11 2013-11-05 Novartis Ag Antigen purification process for pertactin antigen
WO2013043608A1 (en) * 2011-09-20 2013-03-28 Bio-Rad Laboratories, Inc. Removal of virucidal agents from biomolecule preparations
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
CN105007936B (zh) * 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
SG10201911134QA (en) 2015-06-05 2020-01-30 Grace W R & Co Adsorbent bioprocessing clarification agents and methods of making and using the same
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
US11602559B2 (en) 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
AU2019368218B2 (en) 2018-10-22 2026-02-12 New York University Recombinant GP120 protein with V1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
WO1990012086A1 (en) * 1989-03-31 1990-10-18 Washington University Bordetella vaccines
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
CA2188424A1 (en) * 1994-04-28 1995-11-09 Akihiro Suehara Method of separating protective components of bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
AU710538B2 (en) 1999-09-23
PT824358E (pt) 2003-02-28
NZ306391A (en) 1999-03-29
CA2220063C (en) 2003-08-26
NL300804I2 (es) 2016-11-01
EP1234580A1 (en) 2002-08-28
DK1393744T3 (da) 2011-05-30
DE69622555T2 (de) 2003-03-27
LU93036I2 (fr) 2016-06-21
MX9708481A (es) 1998-02-28
EP1234579A1 (en) 2002-08-28
HK1016191A1 (zh) 1999-10-29
EP1233022A1 (en) 2002-08-21
PT826001E (pt) 2002-12-31
ES2182971T3 (es) 2003-03-16
DE69622555D1 (de) 2002-08-29
ATE496634T1 (de) 2011-02-15
CA2220048A1 (en) 1996-11-07
EP1393744B1 (en) 2011-01-26
WO1996034623A1 (en) 1996-11-07
PT1393744E (pt) 2011-05-03
ATE221081T1 (de) 2002-08-15
DK0826001T3 (da) 2002-11-18
AU5494196A (en) 1996-11-21
CN1198099A (zh) 1998-11-04
EP0824358B1 (en) 2002-12-04
US20010009666A1 (en) 2001-07-26
DE69625191D1 (de) 2003-01-16
AU5494096A (en) 1996-11-21
EP0824358A1 (en) 1998-02-25
EP1405643A1 (en) 2004-04-07
EP0826001A1 (en) 1998-03-04
CA2433502A1 (en) 1996-11-07
EP0826001B1 (en) 2002-07-24
BR9608115A (pt) 2004-07-13
CN100387618C (zh) 2008-05-14
CA2220063A1 (en) 1996-11-07
DE69625191T2 (de) 2003-07-10
EP1393744A1 (en) 2004-03-03
FR16C0015I2 (fr) 2017-06-09
CA2220048C (en) 2006-03-07
US6399076B2 (en) 2002-06-04
NZ306392A (en) 1999-04-29
AU715417B2 (en) 2000-02-03
FR16C0015I1 (es) 2016-06-10
DK0824358T3 (da) 2003-01-27
WO1996034883A1 (en) 1996-11-07
CN1193324A (zh) 1998-09-16
EP1233022B1 (en) 2015-12-09
DE69638326D1 (de) 2011-03-10
ATE228851T1 (de) 2002-12-15
BR9608114A (pt) 2000-10-31

Similar Documents

Publication Publication Date Title
ES2182971T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
NL300401I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
ATE127347T1 (de) Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
MX9708480A (es) Vacunas acelulares de pertussis y metodos de preparacion de las mismas.